Press Release
<< Back
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived replay of the presentation will be made available on the same website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005208/en/
Investors:
Investor Relations
+1 781-469-1694
dcalkins@verastem.com
+1 212-600-1902
nate@argotpartners.com
Media:
Corporate Communications
+1 (781) 292-4205
lbuffington@verastem.com
Source: Verastem Oncology